Export to Word
(http://www.niehs.nih.gov//portfolio/index.cfm?do=portfolio.grantdetail&&grant_number=R01ES035439&format=word)
| Principal Investigator: Saini, Yogesh | |
|---|---|
| Institute Receiving Award | North Carolina State University Raleigh |
| Location | Raleigh, NC |
| Grant Number | R01ES035439 |
| Funding Organization | National Institute of Environmental Health Sciences |
| Award Funding Period | 22 Jan 2024 to 31 Oct 2028 |
| DESCRIPTION (provided by applicant): | Project Summary Allergic asthma results in predominantly type-2 (Th2) mucoinflammatory responses including granulocytic inflammation and respiratory epithelial remodeling. These features are also consistently observed in the respiratory tract of rodents exposed repetitively to ozone. Therefore, the ozone-predominated air pollution during the resolution phase of allergic asthma may interfere with the restoration of structure and function in the allergic nasal and pulmonary airspaces. Currently, the molecular and cellular level understanding of the pathogenesis and resolution of either ozone- or allergens-induced Th2 mucoinflammatory respiratory responses has significant knowledge gaps. Therefore, detailed studies addressing these knowledge gaps are essential in promoting our understanding of the interference between ozone pollution and the resolution of allergic inflammation in asthma. Our central hypothesis is that IL-33 regulates the pathogenesis of Th2 inflammation in a cell lineage-specific manner and that targeting of IL-33-ST2 axis will mitigate active inflammation and promote the resolution of mucoinflammatory respiratory disease. The overall objective of this proposal is to test the benefit of inhibition of IL33-ST2 signaling during the pathogenesis and resolution of ozone- and allergens-induced respiratory (nasal and lung) inflammation. In aim 1, we will employ cross-genotype bone marrow chimera approach to elucidate the autocrine versus paracrine IL-33 signaling between hematopoietic progenitor cells (HPCs) and non-HPCs during active ozone/allergens-induced respiratory inflammation. In aim 2, we will test our hypothesis that ozone-exposure disrupts the resolution kinetics of allergens-induced respiratory inflammation. In aim 3, we will test the hypothesis that the genetic and pharmacological inhibition of IL-33-ST2 axis neutralizes ozone-mediated disruption in the resolution of allergens-induced respiratory inflammation. The findings from our studies will enhance our mechanistic understanding of the cell lineage- and signaling direction-specific role of the upstream master regulator of ozone/allergens-induced respiratory inflammation. Impact of ozone on the resolution kinetics of allergic inflammation and the potential for the genetic and pharmacological expedition of ozone-disrupted resolution of allergic airway inflammation will have translational impact. Eventually, these findings may be applied towards the development of anti-inflammation and pro-resolution therapeutics against air-pollution induced Th2 inflammatory diseases. |
| Science Code(s)/Area of Science(s) |
Primary: 69 - Respiratory Secondary: 03 - Carcinogenesis/Cell Transformation |
| Publications | No publications associated with this grant |
| Program Officer | Srikanth Nadadur |